Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-11-28 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于召开2023年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2023 first extraordinary general meeting (临时股东大会) of Meikang Bio-Technology Co., Ltd. It includes information on meeting date, voting procedures (both onsite and online), agenda items including board and supervisory committee elections, amendments to company articles, and stock incentive plans. It also contains attachments such as proxy forms and shareholder registration forms. The document is not a report of voting results, nor a management report or financial statement. It is not an announcement of a report publication but a formal meeting notice with detailed procedural information. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting. The document length is sufficient and contains substantive content about the meeting itself, not just a brief announcement or regulatory filing. Therefore, the classification is AGM-R with high confidence.
2023-11-28 Chinese
董事会专门委员会工作制度(2023年11月）
Governance Information Classification · 100% confidence The document is a detailed internal governance document outlining the working systems and rules for various board committees (Strategic Committee, Nomination Committee, Audit Committee, Remuneration and Assessment Committee) of 美康生物科技股份有限公司. It includes committee compositions, responsibilities, meeting procedures, and authority. It references company law, stock exchange guidelines, and company articles of association. There is no financial data, no audit report, no earnings or annual report content, no voting results, no capital changes, no legal proceedings, no merger or acquisition information, and no presentation or transcript. The document is a governance framework document detailing internal rules and board committee structures and procedures. Therefore, it fits best under Governance Information (CGR). The document length (7725 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive governance document.
2023-11-28 Chinese
独立董事提名人声明-田云鹏
Board/Management Information Classification · 95% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company. It details the qualifications, compliance with laws and regulations, and independence criteria of the nominee. There is no financial data, no report or presentation, no voting results, no legal proceedings, and no mention of any financial period or earnings. The document is a regulatory announcement related to board/management information, specifically about a nomination for the board of directors. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2023-11-28 Chinese
关于选举产生第五届监事会职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new employee representative supervisor to the company's fifth supervisory board. It includes details about the election process, the elected individual's background, and compliance with relevant laws and regulations. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting presentation or voting results. The content focuses on board/management changes specifically related to the supervisory board. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2023-11-28 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a medical device registration certificate issued by a regulatory authority (Zhejiang Provincial Drug Administration). It includes details about the certificate, product, and its expected impact on the company. The document is short (852 characters) and does not contain financial statements or detailed financial data. It is an official announcement about a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-11-28 Chinese
第四届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 21st meeting of the 4th Board of Directors of Meikang Biotechnology Co., Ltd. It includes nominations for the new board, amendments to the company charter and internal rules, approval of a stock incentive plan, and authorization for the board to handle related matters. The document also mentions that these resolutions will be submitted to the upcoming extraordinary general meeting for approval. The content focuses on board and management changes, governance matters, and internal company decisions rather than financial results or reports. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement, but a board meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (6375 characters) and detailed content support this classification with high confidence.
2023-11-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.